Monday , September 20 2021

$ -0,30 EPS expected by Intec Pharma Ltd. (NTEC)



<! –

Trending Stock News

->

November 10, 2018 – Nellie Frank

Intec Pharma Ltd. (NASDAQ: NTEC) Logo

Analysts expect Intec Pharma Ltd. (NASDAQ: NTEC) will report a $ -0.30 EPS on November 21st. They provide an $ 0.10 EPS change or 25.00% of the last quarter's $ -0.4 EPS. Upon deposit of $ -0.34 EPS, Intec Pharma Ltd. analysts believe that EPS growth is -11.76%. During the last trading session, the stock price went up by 0.17% or $ 0.01, reaching $ 5.89. About 126,488 traded shares. From November 11, 2007, Intec Pharma Ltd. (NASDAQ: NTEC) has fallen by 49.01% since November 11, 2017 and has fallen. S & P500 has slightly improved by 64.63%.

Intec Pharma Ltd., a clinical phase biopharmaceutical company, focuses on drug development based on its patented Acordion Pill platform technology in Israel. The company has a market cap of $ 195.70 million. Accordion Pill is an oral delivery system designed to improve the efficacy and safety of existing medicines and medicines through gastric retention and a specific release mechanism. There are currently negative earnings. The company's main product candidate is accordion tablets Carbidopa / Levodopa, which is a Phase III clinical study for the treatment of Parkinson's disease in patients with advanced Parkinson's disease.

Newer Intec Pharma Ltd. (NASDAQ: NTEC) news was published on: Seekingalpha.com, which came out: "Intec Pharma completed its registration in the AP-CD / LD Phase 3 study on advanced PD treatment on October 22, 2018." Stockhouse.com also posted news titled "Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Updates" in November 2018. Searchalpha.com news article entitled: "Intec Pharma: Leading Program Moves On, Moves Forward" with Release Date: October 26, 2018 was also interesting.

Intec Pharma Ltd. (NASDAQ: NTEC) Ratings Chart

– Enter your email address below to receive a concise summary daily newsletter and analytics ratings with our FREE daily email newsletter.

Nellie Frank


Source link